RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/18157142http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/18157142http://www.w3.org/2000/01/rdf-schema#comment"In spite of their having sufficient immunogenicity, tumor vaccines remain largely ineffective. The mechanisms underlying this lack of efficacy are still unclear. Here we report a previously undescribed mechanism by which the tumor endothelium prevents T cell homing and hinders tumor immunotherapy. Transcriptional profiling of microdissected tumor endothelial cells from human ovarian cancers revealed genes associated with the absence or presence of tumor-infiltrating lymphocytes (TILs). Overexpression of the endothelin B receptor (ET(B)R) was associated with the absence of TILs and short patient survival time. The ET(B)R inhibitor BQ-788 increased T cell adhesion to human endothelium in vitro, an effect countered by intercellular adhesion molecule-1 (ICAM-1) blockade or treatment with NO donors. In mice, ET(B)R neutralization by BQ-788 increased T cell homing to tumors; this homing required ICAM-1 and enabled tumor response to otherwise ineffective immunotherapy in vivo without changes in systemic antitumor immune response. These findings highlight a molecular mechanism with the potential to be pharmacologically manipulated to enhance the efficacy of tumor immunotherapy in humans."xsd:string
http://purl.uniprot.org/citations/18157142http://purl.org/dc/terms/identifier"doi:10.1038/nm1699"xsd:string
http://purl.uniprot.org/citations/18157142http://purl.uniprot.org/core/author"Kim S."xsd:string
http://purl.uniprot.org/citations/18157142http://purl.uniprot.org/core/author"Benencia F."xsd:string
http://purl.uniprot.org/citations/18157142http://purl.uniprot.org/core/author"Katsaros D."xsd:string
http://purl.uniprot.org/citations/18157142http://purl.uniprot.org/core/author"Coukos G."xsd:string
http://purl.uniprot.org/citations/18157142http://purl.uniprot.org/core/author"O'Brien-Jenkins A."xsd:string
http://purl.uniprot.org/citations/18157142http://purl.uniprot.org/core/author"Gimotty P.A."xsd:string
http://purl.uniprot.org/citations/18157142http://purl.uniprot.org/core/author"Buckanovich R.J."xsd:string
http://purl.uniprot.org/citations/18157142http://purl.uniprot.org/core/author"Facciabene A."xsd:string
http://purl.uniprot.org/citations/18157142http://purl.uniprot.org/core/author"Balint K."xsd:string
http://purl.uniprot.org/citations/18157142http://purl.uniprot.org/core/author"Sasaroli D."xsd:string
http://purl.uniprot.org/citations/18157142http://purl.uniprot.org/core/date"2008"xsd:gYear
http://purl.uniprot.org/citations/18157142http://purl.uniprot.org/core/name"Nat Med"xsd:string
http://purl.uniprot.org/citations/18157142http://purl.uniprot.org/core/pages"28-36"xsd:string
http://purl.uniprot.org/citations/18157142http://purl.uniprot.org/core/title"Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy."xsd:string
http://purl.uniprot.org/citations/18157142http://purl.uniprot.org/core/volume"14"xsd:string
http://purl.uniprot.org/citations/18157142http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/18157142
http://purl.uniprot.org/citations/18157142http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/18157142
http://purl.uniprot.org/uniprot/#_P48302-mappedCitation-18157142http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/18157142
http://purl.uniprot.org/uniprot/#_Q8BJE1-mappedCitation-18157142http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/18157142
http://purl.uniprot.org/uniprot/P48302http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/18157142
http://purl.uniprot.org/uniprot/Q8BJE1http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/18157142